Biomarker News and Research

RSS

A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule.

Results from Phase IIa clinical trial evaluating VT-111 reported by Viron Therapeutics

Viron Therapeutics Inc., a biotechnology company pioneering the development of immune-modulating protein therapeutics derived from pathogens, today reported results from a Phase IIa clinical trial evaluating VT-111 (Serp-1), an anti-inflammatory protein derived from the myxoma virus.

19 Nov 2009

Covance and Rules-Based Medicine enter into biomarker alliance and services agreement

Covance Inc., a leading provider of drug development services, announced today that it entered into a biomarker alliance and services agreement with Rules-Based Medicine, Inc. (RBM), a leading provider of multiplexed protein biomarker testing to the pharmaceutical industry.

19 Nov 2009

Clinical Data commences patient enrollment in Stedivaze Phase III trial

Clinical Data, Inc. today announced that it has enrolled the first patient in its initial Phase III trial of Stedivaze™, a potential best-in-class vasodilator for use in cardiac stress testing. The study will evaluate the safety and efficacy of Stedivaze (apadenoson) for use as a pharmacologic stress agent in myocardial perfusion imaging (MPI), a method for detecting defects in the blood supply to the heart.

18 Nov 2009

Mayo Clinic licenses non-exclusive rights to Expression Pathology's Liquid Tissue patent

Expression Pathology, a leader in tissue proteomic analysis, today announced Mayo Clinic has licensed non-exclusive rights to Expression Pathology's Liquid Tissue® patent for use in diagnosis of systemic amyloidosis in formalin-fixed tissue.

18 Nov 2009

Abbott and BG Medicine announce a development and commercialization agreement for galectin-3 biomarker

Abbott and BG Medicine, Inc. today announced a development and commercialization agreement for galectin-3, a novel biomarker that may play a role in detecting the development and progression of heart failure. The assay will be developed for Abbott's ARCHITECT immunochemistry instrument platform, specifically the company's i1000SR and i2000SR instruments. The agreement grants Abbott a license to BG Medicine's intellectual property related to galectin-3.

17 Nov 2009

Perceptive Informatics announces the expansion of its medical imaging capabilities for cardiology clinical trials

Perceptive Informatics, a leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation, today announced that it has expanded its leading medical imaging capabilities with advanced nuclear imaging functionality for cardiology clinical trials.

From Parexel 17 Nov 2009

Aterovax presents results of its sPLA2 activity test in the PEACE trial

Aterovax SA, a company developing innovative products for atherosclerosis, today announced data demonstrating that its blood test for secretory phospholipase A2 (sPLA2) activity significantly improves cardiovascular risk prediction in patients with stable coronary artery disease (CAD) over a 5 year period, independent of established risk markers, including C-reactive protein.

17 Nov 2009

Genetic test for familial Dilated Cardiomyopathy launched by PGxHealth

PGxHealth, a division of Clinical Data, Inc., today announced the launch of its genetic test for familial Dilated Cardiomyopathy, an inherited heart disease which is the leading cause of heart transplants and a possible cause of sudden cardiac death.

16 Nov 2009

Genta announces Phase 3 trial results of Genasense

Genta Incorporated today announced preliminary results from AGENDA, the Company’s Phase 3 trial of Genasense® (oblimersen sodium) Injection in patients with advanced melanoma. AGENDA is a randomized, double-blind, placebo-controlled trial of dacarbazine (DTIC) administered with or without Genasense® in patients who have not previously received chemotherapy.

16 Nov 2009

Potential of the European Biomarker Analysis Market to be the focus at upcoming Analyst Briefing

The "omics" revolution of the last decade has ensured that the field of biomarker research will test the frontiers of biomedical research in the coming years. New biomarkers are discovered each day and this rapid development promises excellent growth potential for the biomarker analysis market. However, due to various challenges faced in biomarker validation and assay development, there is a huge lag between the time that a biomarker is discovered in the laboratory and the time it is actually commercialized.

16 Nov 2009

Positive results from Lexicon Pharmaceuticals' LX1031 Phase 2 study for IBS

Lexicon Pharmaceuticals, Inc. announced today that the company's investigational new drug, LX1031, a tryptophan hydroxylase (TPH) inhibitor, demonstrated positive results in clinically important parameters for the treatment of non-constipating irritable bowel syndrome (IBS).

13 Nov 2009

Mouth: A diagnostic indicator for general health

The mouth or oral cavity area is an excellent indicator of the whole body's health, says Mao, who is the chair of the new Department of Oncology and Diagnostic Sciences at the School.

13 Nov 2009

Cequent Pharmaceuticals proposes the first test of an orally administered RNA interference drug in humans

Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, has announced that it has filed its first IND (investigational new drug) application with the U.S. Food and Drug Administration (FDA).

12 Nov 2009

Predictive power of Champions Biotechnology's Biomerk Tumorgraft platform to be presented

Champions Biotechnology, Inc., an oncology drug development company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, has announced that two of its studies regarding its application in oncology drug development and personalized medicine have been selected for a poster and oral presentation at the upcoming AACR-EORTC conference in Boston.

12 Nov 2009

New Cat B 750 FAST imaging agent launched by VisEn Medical

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new Cat B 750 FAST(TM) imaging agent for measuring and monitoring cathepsin B activity associated with disease progression and therapeutic response in vivo. Cathepsin B expression is well known as a key biomarker and therapeutic target in a range of diseases, including atherosclerosis, oncology, and arthritis.

12 Nov 2009

USPTO issues patent number to Vermillion's biomarkers for detecting ovarian cancer

Vermillion, Inc., a molecular diagnostics company, today announced that the U.S. Patent Office (USPTO) has issued patent number 7,605,003 titled "Use of biomarkers for detecting ovarian cancer" to the Company for the discovery of biomarkers for ovarian cancer.

12 Nov 2009

Stapled Peptides directly inhibit the Notch transcription factor complex

Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collaborators, James E. Bradner, MD of the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT, and Gregory L. Verdine, PhD, Professor of Chemistry at Harvard University, published research in Nature entitled, “Direct Inhibition of the Notch Transcription Factor Complex.”

12 Nov 2009

Millennium Laboratories announces new clinical quantitative assay and drug screening tests for healthcare

Millennium Laboratories, a leading provider of therapeutic drug monitoring and education to physicians and staff treating chronic pain patients, announced today the company’s development and validation of a clinical quantitative assay for the new drug tapentadol (Nucynta™) by liquid chromatography/tandem mass spectrometry (LC-MS/MS).

12 Nov 2009

Stapled Peptides can inhibit key intracellular biological targets, says new research

Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collaborators, James E. Bradner, MD of the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT, and Gregory L. Verdine, PhD, Professor of Chemistry at Harvard University, published research in Nature entitled, "Direct Inhibition of the Notch Transcription Factor Complex." Results presented in the paper showed that Stapled Peptides can potently and directly inhibit the transcription factor Notch, an oncogene implicated in cancer cell proliferation and survival.

12 Nov 2009

NMO patients are misdiagnosed with Multiple Sclerosis, says Mayo Clinic neurologist

Thousands of Neuromyelitis Optica (NMO) patients are potentially being misdiagnosed with Multiple Sclerosis (MS), according to Mayo Clinic Neurologist Sean Pittock, M.D., largely due to lack of awareness of NMO within the medical community.

12 Nov 2009

Biomarker News and Research

Further Reading

Results from Phase IIa clinical trial evaluating VT-111 reported by Viron Therapeutics

Covance and Rules-Based Medicine enter into biomarker alliance and services agreement

Clinical Data commences patient enrollment in Stedivaze Phase III trial

Mayo Clinic licenses non-exclusive rights to Expression Pathology's Liquid Tissue patent

Abbott and BG Medicine announce a development and commercialization agreement for galectin-3 biomarker

Perceptive Informatics announces the expansion of its medical imaging capabilities for cardiology clinical trials

Aterovax presents results of its sPLA2 activity test in the PEACE trial

Genetic test for familial Dilated Cardiomyopathy launched by PGxHealth

Genta announces Phase 3 trial results of Genasense

Potential of the European Biomarker Analysis Market to be the focus at upcoming Analyst Briefing

Positive results from Lexicon Pharmaceuticals' LX1031 Phase 2 study for IBS

Mouth: A diagnostic indicator for general health

Cequent Pharmaceuticals proposes the first test of an orally administered RNA interference drug in humans

Predictive power of Champions Biotechnology's Biomerk Tumorgraft platform to be presented

New Cat B 750 FAST imaging agent launched by VisEn Medical

USPTO issues patent number to Vermillion's biomarkers for detecting ovarian cancer

Stapled Peptides directly inhibit the Notch transcription factor complex

Millennium Laboratories announces new clinical quantitative assay and drug screening tests for healthcare

Stapled Peptides can inhibit key intracellular biological targets, says new research

NMO patients are misdiagnosed with Multiple Sclerosis, says Mayo Clinic neurologist

Breath Biopsy®: The Complete Guide eBook

Passing on Polycystic Ovary Syndrome: Health risks for male offspring of women with PCOS

Top-Down Proteomics: Bridging the Genotype-to-Phenotype Gap

Bridging the Gap between Academia and Industry: The Power of Collaboration in Life Sciences

Latest Life Science News